Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldose reductase inhibitor-diabetes complications trial (ADCT)

Next Previous
X
Search
Trial Profile

Aldose reductase inhibitor-diabetes complications trial (ADCT)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epalrestat (Primary)
  • Indications Diabetic nephropathies; Diabetic neuropathies
  • Focus Therapeutic Use
  • Acronyms ADCT

    • Most Recent Events

    • 01 Sep 2007 Results have been published in journal of Diabetes Research and Clinical Practice.
    • 21 Feb 2007 New trial record.
    • 01 Jun 2005 The primary endpoint has been met (Change from baseline in median motor nerve conduction velocity (MNCV) at 3 years) according to the results published at 65th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top